Nobel laureate Carolyn Bertozzi joins cell therapy biotech Acepodia as chief scientific advisor
Carolyn Bertozzi helped kindle the spark that became cell therapy biotech Acepodia while the company’s co-founder, Sonny Hsiao, was still a PhD student, working in Bertozzi’s lab at UC Berkeley.
More than a decade later, the Nobel laureate has been named Acepodia’s chief scientific advisor, the biotech announced Monday.
Acepodia, founded in 2017, is now in the clinic, starting with the first two candidates from its antibody-cell conjugate platform, which pairs targeted monoclonal antibodies with immune cells that attack cancer. The idea is similar to antibody-drug conjugates and builds upon groundbreaking discoveries in click chemistry that won Bertozzi the Nobel Prize in Chemistry in 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
